Thyrocare Technologies Ltd (THYROCARE) AI Stock Analysis

Thyrocare Technologies Ltd

(NSE:THYROCARE)

Select Model

Rating:68Neutral

Price Target:INR 498.00▲(8.97% Upside)

Action:reiterated

Date:10/31/26

Thyrocare's overall score of 68 is heavily supported by its fortress-like balance sheet, strong profitability, and excellent cash flow generation (weighted at 50%). However, the score is significantly weighed down by stark technical weakness, as the stock is in a clear downtrend below all major moving averages, and a premium valuation multiple that demands caution despite robust underlying fundamentals.

Positive Factors

Conservative Balance SheetVery low leverage gives Thyrocare financial flexibility and reduces the burden of interest obligations. The sharp improvement in ROE also indicates that the company is generating stronger returns from its equity base, supporting durable capital efficiency.

Negative Factors

Margin VolatilityLarge historical swings in gross and overall margins make current profitability less predictable. Even with healthy FY2026 margins, this volatility creates uncertainty about how consistently revenue growth will translate into earnings and limits confidence in long-term margin sustainability.

Thyrocare Technologies Ltd (THYROCARE) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 72.63B
Dividend Yield: 2.04%
Average Volume (3M): 113.54K
Price to Earnings (P/E): 50.4
Beta (1Y): 0.63
Revenue Growth: 21.99%
EPS Growth: 12.77%
Country: India
Employees: 2,092
Sector: General
Sector Strength: 55
Industry: Medical - Diagnostics & Research

Thyrocare Technologies Ltd Business Overview & Revenue Model

Company Description

Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across th...

How the Company Makes Money

Thyrocare primarily makes money by providing diagnostic testing services for a fee. Its main revenue stream is the sale of pathology/laboratory tests and bundled preventive health check-up packages, where customers (individuals or institutions) pay p...

Thyrocare Technologies Ltd Financial Statement Overview

Summary

Exceptional financial health characterized by solid revenue recovery, a nearly debt-free balance sheet, and a high return on equity of 27.8%. Strong operating efficiencies and stellar cash flow conversion provide significant stability and liquidity.

Income Statement

85Very Positive

Balance Sheet

90Very Positive

Cash Flow

88Very Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	8.76B	8.29B	6.87B	5.72B	5.27B	5.89B
Gross Profit	4.46B	3.10B	4.96B	1.81B	3.63B	4.19B
EBITDA	2.88B	2.65B	2.04B	1.48B	1.31B	2.64B
Net Income	1.76B	1.63B	915.10M	707.60M	644.90M	1.76B
Balance Sheet
Total Assets	0	7.47B	6.93B	6.44B	6.33B	6.08B
Cash, Cash Equivalents and Short-Term Investments	1.90B	2.31B	1.92B	1.77B	1.51B	1.39B
Total Debt	0	506.90M	246.80M	423.40M	233.10M	207.00M
Total Liabilities	-5.86B	1.61B	1.46B	1.16B	975.00M	810.90M
Stockholders Equity	5.86B	5.86B	5.47B	5.27B	5.34B	5.27B
Cash Flow
Free Cash Flow	1.11B	1.95B	1.46B	1.06B	856.60M	755.80M
Operating Cash Flow	1.27B	2.16B	1.91B	1.68B	1.29B	1.13B
Investing Cash Flow	47.10M	-260.80M	-525.20M	-912.80M	-389.90M	-235.70M
Financing Cash Flow	-1.18B	-1.70B	-1.30B	-848.00M	-861.80M	-894.10M

Thyrocare Technologies Ltd Technical Analysis

Technical Analysis SentimentNegative

Last Price457.00

Price Trends

50DMA539.60Negative

100DMA549.70Negative

200DMA483.61Negative

Market Momentum

MACD-18.10Negative

RSI36.74Neutral

STOCH64.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Negative. The current price of 457.00 is below the 20-day moving average (MA) of 494.66, below the 50-day MA of 539.60, and below the 200-day MA of 483.61, indicating a bearish trend. The MACD of -18.10 indicates Negative momentum. The RSI at 36.74 is Neutral, neither overbought nor oversold. The STOCH value of 64.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:THYROCARE.

Thyrocare Technologies Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:THYROCARE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:LALPATHLAB	74Outperform	INR 319.97B	58.77	―	0.84%	14.29%	5.55%
IN:VIJAYA	71Outperform	INR 149.06B	79.30	―	0.14%	20.18%	24.71%
IN:VIMTALABS	69Neutral	INR 21.67B	27.15	―	0.41%	14.22%	7.17%
IN:THYROCARE	68Neutral	INR 72.74B	50.42	―	2.04%	21.99%	12.77%
IN:KRSNAA	61Neutral	INR 16.35B	16.77	―	0.40%	10.19%	20.99%
IN:METROPOLIS	59Neutral	INR 113.09B	56.06	―	0.37%	21.80%	31.84%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:THYROCARE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:THYROCARE	Thyrocare Technologies Ltd	457.00	2.20	0.48%
IN:KRSNAA	Krsnaa Diagnostics Limited	504.10	-281.30	-35.82%
IN:LALPATHLAB	Dr. Lal PathLabs Limited	1906.30	296.36	18.41%
IN:METROPOLIS	Metropolis Healthcare Ltd.	545.15	46.06	9.23%
IN:VIJAYA	Vijaya Diagnostic Centre Ltd.	1447.25	429.81	42.24%
IN:VIMTALABS	Vimta Labs Limited	484.85	-194.79	-28.66%

Thyrocare Technologies Ltd Corporate Events

Thyrocare Plans October 29 Call on Q2 FY2026-27 Results

Oct 22, 2026

Thyrocare Technologies Ltd has scheduled an earnings conference call for analysts and investors to discuss its unaudited financial results for the quarter and half year ended September 30, 2026. The call will be held on Thursday, October 29, 2026, at...

Thyrocare publishes postal ballot notice and opens e‑voting for shareholders

Sep 29, 2026

Thyrocare Technologies Ltd has notified the stock exchanges that it has published its postal ballot notice in English and Marathi newspapers, confirming that the ballot documents have been dispatched and providing details of the e‑voting period...

Thyrocare exits radiology arm with Rs 141 crore sale to Trovera

Sep 21, 2026

Thyrocare Technologies Ltd has approved the sale of its entire shareholding in Nueclear Healthcare Ltd, its material wholly owned subsidiary operating the radiology and diagnostic imaging business, to Trovera Healthcare Pvt Ltd for a total considerat...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Thyrocare Technologies Ltd AI Stock Analysis